This year Vytorin has failed two clinical trials meant to show its benefits.
今年，本要证明Vytorin有效的两个临床试验失败了。
In the United States, prescriptions for Vytorin and Zetia have fallen 40 percent this year.
在美国，今年Vytorin和Zetia的处方量下跌了40%。
About half the patients were given Vytorin and the other half placebo, and were tracked for an average of more than four years.
接收调查的患者有一半服用维多灵，另一半人服用安慰剂，平均被追踪观察四年之久。
The Enhance trial was not an events trial and was not intended to study whether Zetia or Vytorin were effective at reducing heart attacks.
Enhance试验并不是大规模的临床试验，因为这项试验不是为了研究Zetia或者Vytorin是否对降低心脏病的发病率有效果。
Roger Blumenthal of Johns Hopkins University says Vytorin should not be tried as the first anti-cholesterol remedy for new patients: statins should.
约翰霍普金斯大学的RogerBlumenthal认为Vytorin将不会被当作降低胆固醇的首选药物，但是他汀类药物本身还应当是首选。
Dr. Terje Pedersen, the Norwegian cardiologist who conducted the trial, said he also doubted that Vytorin caused the excess of cancers seen in the study.
主管这个试验的挪威心脏病专家TerjePedersen博士说，他也对研究中Vytorin额外引起癌症的现象表示怀疑。
In all, 136 of about 11, 000 people taking Vytorin in the three trials have died of various kinds of cancer, compared with 95 out of 11, 000 who took placebo or simvastatin alone.
三个试验中，总共大约有11000个病人服用Vytorin，其中有136人死于各种癌症，而与之相对照的服用安慰剂或只用simvastatin的11000个病人中，只有95人死于癌症。
And even Dr Nissen, a leading critic of Vytorin, concedes that those claiming that all cholesterol science is bunk are going too far; he thinks statins, at least, have a bright future.
即使是Vytorin的主要批评者Nissen博士也承认那些对所有降胆固醇药物统统否定的做法有些过分，他认为他汀类药物本身会有光明的未来。
Dr Nissen, a leading cardiologist, is up in arms over the way Merck and Schering-Plough, two American pharmaceutical giants, have handled a clinical trial of Vytorin, a blockbuster anticholesterol
Nissen博士，这位美国知名的心脏病专家，激烈的反对两个美国大型制药公司默克和先灵葆雅对Vytorin（一种由这两家公司联合研制的重磅炸弹级别的抗胆固醇的处方药）的临床试验所采取的做法。
Dr Nissen, a leading cardiologist, is up in arms over the way Merck and Schering-Plough, two American pharmaceutical giants, have handled a clinical trial of Vytorin, a blockbuster anticholesterol
Nissen博士，这位美国知名的心脏病专家，激烈的反对两个美国大型制药公司默克和先灵葆雅对Vytorin（一种由这两家公司联合研制的重磅炸弹级别的抗胆固醇的处方药）的临床试验所采取的做法。
应用推荐